Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 14, Issue 2, Pages 273-297Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728210902918299
Keywords
cell based therapies; cognitive; dopamine; environmental influences; GABA; glutamate; Huntington's disease; motor; neuroprotective; neuropsychiatric; pharmacology
Categories
Funding
- Cure PD
- University of Cambridge
Ask authors/readers for more resources
Huntington's disease (HD) is a relentless neurodegenerative disease that results in profound disability through a triad of motor, cognitive and neuropsychiatric symptoms. At present, there are very few therapeutic interventions available with the exception of a limited number of drugs that offer mild symptomatic relief. Although the genetic basis of the disease has been identified, the mechanisms behind the cellular pathogenesis are still not clear and as a result no candidate drugs with the potential for disease modification have been found clinically until now. One of the major limitations in assessing the usefulness of drug treatments in HD is the lack of well-designed, double-blind, placebo-controlled clinical trials. Most studies have been open-label, using a small number of patients and tend to concentrate on the motor features of the disease, primarily the chorea. This review discusses the treatments now used for HD before evaluating the newer drugs at present being explored in both the clinic and in the laboratory in mouse models of the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available